Evofem Biosciences Files Q3 2024 10-Q
Ticker: EVFM · Form: 10-Q · Filed: Nov 14, 2024 · CIK: 1618835
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
Related Tickers: EVFM
TL;DR
Evofem Biosciences Q3 2024 10-Q filed. Check financials.
AI Summary
Evofem Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter of 2024, detailing its revenue, expenses, and net loss. Key financial data and operational updates are provided within the filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational status of Evofem Biosciences, Inc. as of the end of the third quarter of 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Evofem Biosciences faces inherent risks related to drug development, regulatory approvals, market competition, and financial performance, which are typical for the industry.
Key Numbers
- 2024-09-30 — Period End Date (The 10-Q covers financial data up to this date.)
- 2024-11-14 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- 2024-11-14 (date) — Filing date of the 10-Q
- Neothetics, Inc. (company) — Former company name
- 2014-09-05 (date) — Date of name change from Neothetics, Inc.
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the nine months ended September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on November 14, 2024.
What was Evofem Biosciences, Inc.'s former company name?
Evofem Biosciences, Inc.'s former company name was Neothetics, Inc.
On what date did the company change its name from Neothetics, Inc.?
The company changed its name from Neothetics, Inc. on September 5, 2014.
What is the company's Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,753 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2024-11-14 17:18:51
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share EVFM OTCQB Indicate by
Filing Documents
- form10-q.htm (10-Q) — 2123KB
- ex10-14.htm (EX-10.14) — 80KB
- ex10-15.htm (EX-10.15) — 79KB
- ex31-1.htm (EX-31.1) — 20KB
- ex31-2.htm (EX-31.2) — 19KB
- ex32-1.htm (EX-32.1) — 12KB
- 0001493152-24-046060.txt ( ) — 10503KB
- evfm-20240930.xsd (EX-101.SCH) — 63KB
- evfm-20240930_cal.xml (EX-101.CAL) — 70KB
- evfm-20240930_def.xml (EX-101.DEF) — 328KB
- evfm-20240930_lab.xml (EX-101.LAB) — 492KB
- evfm-20240930_pre.xml (EX-101.PRE) — 412KB
- form10-q_htm.xml (XML) — 1963KB
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS 1 PART I. FINANCIAL INFORMATION Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Income (Loss) 5 Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders' Deficit 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.
Controls and Procedures
Controls and Procedures 46 PART II. OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 48 Item 1A.
Risk Factors
Risk Factors 48 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52 Item 3. Defaults Upon Senior Securities 52 Item 4. Mine Safety Disclosures 52 Item 5. Other Information 52 Item 6. Exhibits 53
Signatures
Signatures 54 FORWARD-LOOKING This quarterly report on Form 10-Q (Quarterly Report), contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." All statements, other than statements of historical facts, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These
forward-looking statements include, among other things, statements about
forward-looking statements include, among other things, statements about: our ability to maintain compliance with listing standards of the OTCQB Venture Market to maintain the listing of our shares thereon; our ability to continue as a going concern; the Notice of Default and cancellation of Forbearance Agreement received by FuturePak, LLC and any potential legal action(s) against the Company and its assets that could be taken; the requirement to change the name of Phexxi the consummation of the transactions contemplated by the Amended and Restated Merger Agreement, as amended, and documents related thereto; the Support Agreements related to the transactions contemplated under the Amended and Restated Merger Agreements as amended; our ability to successfully integrate and commercialize SOLOSEC (secnidazole) 2g oral granules (SOLOSEC); our ability to remediate the material weaknesses in our internal controls and procedures identified by management; our ability to obtain necessary approvals of any corporate action(s) needing stockholder, FINRA, or other approvals; our ability to file Annual and Quarterly Reports on a timely basis; our ability to raise additional capital to fund our operations if and as needed; our ability to achieve and sustain profitability; our estimates regarding our future performance including, without limitation, any estimates of potential future revenues; estimates regarding market size; our estimates regarding expenses, revenues, financial performance and capital requirements, including the length of time our capital resources will sustain our operations; our ability to comply with the provisions and requirements of our debt arrangements, to avoid future defaults pursuant to our debt arrangements and to pay amounts owed, including any amounts that may be accelerated, pursuant to our debt arrangements; estimates regarding health care providers' (HCPs) recommendations of Phexxi (lactic acid, citric acid, and pot